Metastatic Breast Cancer With HER2 Positive

Also known as: Metastatic HER2/Neu-positive Breast Cancer / HER2 Positive Metastatic Breast Cancers / Metastatic HER2-Positive Breast Cancer / Her2 Positive Metastatic Breast Cancer / Breast Cancer; HER2-positive; Metastatic / HER2-positive Metastatic Breast Cancer / HER-2 Positive Metastatic Breast Cancer / Metastasis from human epidermal growth factor 2 positive carcinoma of breast (disorder)

DrugDrug NameDrug Description
DB14967MargetuximabAn Fc-engineered human/mouse chimeric IgG1κ anti-HER2 monoclonal antibody indicated for patients with HER2-positive metastatic breast cancer.
DB14962Trastuzumab deruxtecanAn antibody used to treat certain types of unresectable or metastatic HER2 positive breast cancer.
DrugDrug NamePhaseStatusCount
DB11595Atezolizumab1Completed1
DB01101Capecitabine1Completed1
DB00958Carboplatin1Completed1
DB00531Cyclophosphamide1Completed1
DB00531Cyclophosphamide1Recruiting1
DB01248Docetaxel1Completed1
DB00997Doxorubicin1Completed1
DB17573Evorpacept1Recruiting1
DB01073Fludarabine1Recruiting1
DB14967Margetuximab1Completed1
DB01229Paclitaxel1Withdrawn1
DB06366Pertuzumab1Completed1
DB06366Pertuzumab1Recruiting1
DB00072Trastuzumab1Completed2
DB14962Trastuzumab deruxtecan1Recruiting2
DB16342Trastuzumab duocarmazine1Withdrawn1
DB05773Trastuzumab emtansine1Completed1
DB05773Trastuzumab emtansine1Recruiting1
DB11652Tucatinib1Completed1
DB11652Tucatinib1Recruiting1
DB15471Zanidatamab1Recruiting1
DB12015Alpelisib1 / 2Recruiting1
DB01101Capecitabine1 / 2Unknown Status1
DB00997Doxorubicin1 / 2Terminated1
DB00947Fulvestrant1 / 2Recruiting1
DB01259Lapatinib1 / 2Terminated1
DB01259Lapatinib1 / 2Unknown Status1
DB14993Pyrotinib1 / 2Unknown Status1
DB00072Trastuzumab1 / 2Recruiting1
DB11652Tucatinib1 / 2Recruiting1
DB18290Anvatabart opadotin2Recruiting1
DB11595Atezolizumab2Active Not Recruiting1
DB01101Capecitabine2Active Not Recruiting1
DB01101Capecitabine2Recruiting2
DB01248Docetaxel2Completed1
DB00773Etoposide2Terminated1
DB00441Gemcitabine2Active Not Recruiting1
DB17457Inetetamab2Active Not Recruiting1
DB06366Pertuzumab2Active Not Recruiting2
DB14993Pyrotinib2Active Not Recruiting1
DB14993Pyrotinib2Recruiting1
DB00072Trastuzumab2Active Not Recruiting2
DB00072Trastuzumab2Completed1
DB00072Trastuzumab2Recruiting2
DB00072Trastuzumab2Terminated1
DB11652Tucatinib2Recruiting2
DB00361Vinorelbine2Recruiting1
DB01101Capecitabine3Active Not Recruiting1
DB01101Capecitabine3Unknown Status1
DB01248Docetaxel3Unknown Status1
DB01259Lapatinib3Unknown Status1
DB06366Pertuzumab3Active Not Recruiting1
DB14993Pyrotinib3Active Not Recruiting1
DB14993Pyrotinib3Unknown Status1
DB00072Trastuzumab3Active Not Recruiting1
DB00072Trastuzumab3Unknown Status1
DB14962Trastuzumab deruxtecan3Active Not Recruiting1
DB18411AnbenitamabNot AvailableTerminated1
DB00947FulvestrantNot AvailableTerminated1
DB09073PalbociclibNot AvailableTerminated1
DB06366PertuzumabNot AvailableRecruiting1
DB00072TrastuzumabNot AvailableRecruiting1